RADIOPHARM THERANOSTICS LTD (RADX) Stock Analyst Ratings
USA - NASDAQ:RADX - ADR
5.33 USD
-0.23 (-4.14%)
ChartMill assigns a Buy % Consensus number of 80% to RADX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.98. This target is 12.19% above the current price.
RADX was analyzed by 7 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about RADX.
In the previous month the buy percentage consensus was at a similar level.
RADX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-21 | Brookline Capital | Initiate | Buy |
| 2025-05-01 | Maxim Group | Initiate | Buy |
| 2025-03-12 | B. Riley Securities | Initiate | Buy |
RADIOPHARM THERANOSTICS LTD / RADX FAQ
What do analysts expect the price target to be for RADIOPHARM THERANOSTICS LTD (RADX)?
7 analysts have analysed RADX and the average price target is 5.98 USD. This implies a price increase of 12.19% is expected in the next year compared to the current price of 5.33.
How do analysts rate RADIOPHARM THERANOSTICS LTD (RADX)?
The consensus rating for RADIOPHARM THERANOSTICS LTD (RADX) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for RADX stock?
The number of analysts covering RADIOPHARM THERANOSTICS LTD (RADX) is 7.